Close Menu
Home › AmoyDx Lung Cancer CDx Approved in South Korea

AmoyDx Lung Cancer CDx Approved in South Korea

Oct 12, 2018
|
staff reporter

NEW YORK (GenomeWeb) — Chinese diagnostics firm AmoyDx announced this month that South Korea's Ministry of Food and Drug Safety has approved its ROS1 fusion assay as a companion diagnostic for Pfizer's non-small cell lung cancer (NSCLC) drug Xalkori (crizotinib).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
19
Featured Webinar

Evolution of Tumor Profiling in a Clinical Lab: Moving toward Comprehensive Genomic Profiling

Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

What's Popular?

In Molecular Diagnostics

  1. NCCN Updates Genetic Testing Guidelines for Assessing Breast, Ovarian, Pancreatic Cancer Risk

  2. Hologic Vaginitis Tests Offer Improvements Over Gold Standard Methods

    Premium

  3. Local Coverage Determinations Roundup: Transplant Genomics, Opko Health

  4. FDA Approves Foundation Medicine CDx for Novartis Breast Cancer Drug Piqray

  5. Illumina, ArcherDx Expand Partnership on NGS IVD Tests

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.